The investment planning of the domestic pharmaceutical industry is in full progress, after the approval of 53 investments amounting to 519.28 million euros in the framework of the action “Reform of the clawback system & offsetting it with research and investment costs”, of the National Recovery and Resilience Plan “Greece 2.0”. These 53 projects meet all the participation conditions and eligibility conditions, while 85% of them are implemented by Greek companies. The above projects are part of the Greek pharmaceutical industry’s dynamic plan for investments totaling 1.2 billion euros over a four-year period, the Panhellenic Pharmaceutical Industry Association (PEF) says in a statement.
“These investments have a unique multiplier effect on the economy, through the creation of added value that stays and is reinvested in the country. In addition, through these investments, Greece’s trade balance deficit is reduced, as it ensures that the needs are met by the domestic production of medicines, while at the same time, employment is strengthened with permanent, specialized and well-paid new jobs”, emphasizes (PEF).
He notes that with the completion of the investment program, Greece will be able to emerge as a European “hub” for production, research and innovation, while the independence from drug imports from third countries, such as China and Asia, will be completed. At the same time, domestic production will be further strengthened and exports abroad will increase, thus contributing to the reduction of the trade deficit.
Commenting on the approval of the 53 investments within the framework of the National Recovery and Resilience Plan “Greece 2.0”, the president of the Panhellenic Pharmaceutical Industry Association, Theodoros Tryfon, said:
“The Greek pharmaceutical industry is actively participating in the effort to recover the national economy. With the help of the three co-competent ministries and in the context of offsetting the clawback with the sector’s productive investments, investments are implemented that have multiplier benefits for society. In particular, they protect the health system and pharmaceutical care, ensuring the adequacy of the market and the access of patients to all necessary treatment, reducing the dependence on imports, while at the same time they will lead to the emergence of our country as a hub of research and production of medicines in the wider region of SE Europe”.
SOURCE: AMPE
Source: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
